“If I take 2.5ml of blood from you today, after half a year, we can show you several jars of personalised mini-hearts of yours, beating right in front of you,” says Novoheart founder Professor Ronald Li. This innovative and world's first technology is being used for a wide range of applications, such as the development of next-generation custom-tailored drugs, transplantable bio-artificial bandages and organs. Professor Ronald Li was the Founding Director of the Stem Cell & Regenerative Medicine Consortium (SCRMC) and S Y and H Y Cheng Endowed Professor in Stem Cell Biology and Regenerative Medicine at HKU. He is currently affiliated with the Li Dak-Sum Center for Regenerative Medicine at HKU, and the Ming-Wai Lau Center for Regenerative Medicine, Karolinska Institute, Sweden. Since 1901, Karolinska Institute has been selecting Nobel Laureates in Medicine & Physiology. Previously, Professor Li was on the faculty of the Section of Cardiovascular Cell & Tissue Engineering at Icahn School of Medicine at Mount Sinai in Manhattan, NY, and the University of California, Davis where he led the Human Embryonic Stem Cell Consortium. Before he was recruited to CA in light of the state’s USD$3-billion stem cell initiative Proposition 71, Professor Li was Assistant Professor of Medicine at the Johns Hopkins University. During Prof. Li’s tenure at Johns Hopkins School of Medicine, he was a 2-time recipient of the Top Young Faculty Award (2002, 2004), the Top Prize for the Young Investigator Basic Research (2001) and Top Postdoctoral Fellow (2001). Professor Li’s other accolades include American Heart Association (AHA)’s Best Study of 2005 and Ground-breaking Study of the 2006, Young Investigator Award from the Heart Rhythm Society (2002), and the Career Development Award from the Cardiac Arrhythmias Research & Education Foundation (2001). Professor Li’s main interest is in cardiac tissue engineering, with over 130 publications. Professor Li has served as a panel member of a range of international funding bodies including the NIH, AHA, Association Francaise contre les Myopathies, United States-Israel Binational Science Foundation, Research Grant Council of HK, Stem Cell Consortium, A*STAR/Biopolis of Singapore, Wellcome Trust and MRC of the UK, etc. Professor Li’s inventions have led to several start-ups in the U.S. and Hong Kong, with the latest one being Novoheart, which specializes in engineering human heart tissues and chambers for revolutionizing drug discovery and development as well as cell-based regenerative heart therapies.